NCT06744868 - A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

September 22, 2024

Study Completion Date

September 22, 2024

Conditions

Healthy

Interventions

DRUG

THDBH120 injection (SAD)

Participants received escalating single doses of THDBH120 by subcutaneous injection.

DRUG

Placebo of THDBH120 injection (SAD)

Participants received single dose of placebo by subcutaneous injection.

DRUG

THDBH120 injection (MAD)

Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.

DRUG

Placebo of THDBH120 injection (MAD)

Participants received placebo once weekly for four weeks by subcutaneous injection.

Trial Locations (1)

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Tonghua Dongbao Pharmaceutical Co.,Ltd

INDUSTRY